MetaCap

AC Immune SA (ACIU)

NASDAQ: ACIUHealth CareBiotechnology: Pharmaceutical PreparationsUSD

1.95-0.18 (-8.45%)

At close: Nov 20, 4:00 PM ET · Delayed 15 min

ACIU stock chart

Technical analysis

Key statistics

All statistics
Market cap
$193.88M
EPS (TTM)
-$0.44
52-week range
1.93 – 3.90
Day range
1.93 – 2.15
Volume / Avg
297.66K / 198.81K
Beta
—

52-week range

$1.93$3.90

ACIU stock today

AC Immune SA (ACIU) closed at $1.95 on Nov 20, down 8.45% (-$0.18), versus the S&P 500's 3.70% decline. At this level, ACIU sits near the bottom of its 52-week range of $1.93 to $3.90: 50.0% below the high, set on Jan 23, 2026 and 1.0% above the low. ACIU is down 37.9% year to date, underperforming the S&P 500 (+1.2%). Over the past 12 months, the stock has lost 35.0%.

AC Immune SA has posted a net loss over the last twelve months (EPS of -$0.44), so its P/E ratio is not meaningful.

Summary generated from market data by MetaCap's automated system. Methodology

About AC Immune SA

Company profile

AC Immune SA, a clinical stage biopharmaceutical company, discovers, designs, and develops medicines, and therapeutic and diagnostic products for the prevention and treatment of neurodegenerative diseases associated with protein misfolding. The company's SupraAntigen and Morphomer platforms are designed to generate biologics and small molecules, which selectively interact with misfolded proteins that are common in a range of neurodegenerative diseases. It develops Crenezumab, a humanized, conformation specific monoclonal antibody used to slow Alzheimer's disease (AD) progression; and Semorinemab, an investigational monoclonal anti-Tau antibody that targets the N-terminal portion of the Tau protein and is designed to bind to Tau and slow its spread between neurons for the treatment of AD.

Industry
Biotechnology: Pharmaceutical Preparations
CEO
Dr. Martin Zugel M.D., Ph.D.
Headquarters
Lausanne
Employees
90
IPO year
2016

Analyst forecast

Forecast

Consensus (4 analysts)

strong_buy

Avg. price target

$8.41+331.28%

  • Strong buy 0
  • Buy 4
  • Hold 0
  • Sell 0
  • Strong sell 0

Target range

Low $5.42High $11.65

Ratings and targets reflect third-party analyst opinions, not MetaCap recommendations.

Earnings

Earnings history
Last reported (Sep/2026)
Nov 4, 2026
EPS actual vs est.
$-0.16 vs $-0.22
Surprise
+27.27%

ACIU news

All ACIU news

AC Immune SA peers

Health Care sector
ACIU peer companies
CompanyPrice% ChgMarket capCompare
ANTXAN2 Therapeutics Inc.5.08-2.68%$192.75Mvs ACIU
YARWYarrow Bioscience Inc.12.90-9.35%$196.53Mvs ACIU
BIOABioAge Labs Inc.4.28-9.13%$196.67Mvs ACIU
NGENNervGen Pharma Corp.1.85-3.91%$198.55Mvs ACIU
RNACCartesian Therapeutics Inc.6.14+4.24%$187.29Mvs ACIU
DRUGBright Minds Biosciences Inc.20.40-1.45%$201.23Mvs ACIU
BCYCBicycle Therapeutics plc ADR2.90-4.92%$203.27Mvs ACIU
FTHFaeth Therapeutics Inc.7.88-9.32%$203.65Mvs ACIU

Indexes, lists and sector

AC Immune SA stock FAQ

What is AC Immune SA's stock price today?

ACIU last traded at $1.95 as of Nov 20, 4:00 PM EST, down 8.45% on the day. Prices are delayed at least 15 minutes.

Who is AC Immune SA's CEO?

Dr. Martin Zugel M.D., Ph.D. is the chief executive officer of AC Immune SA, which has about 90 employees.

What is the ACIU 52-week high?

The 52-week high for ACIU is $3.90 and the 52-week low is $1.93. The stock is currently 50.0% below its high.

Compare ACIU